Skip to main content
Premium Trial:

Request an Annual Quote

Todos Medical Acquires US Commercial Rights to Osang Healthcare Coronavirus Test

NEW YORK — Todos Medical said on Tuesday that it has acquired US rights to sell Osang Healthcare's GeneFinder COVID-19 Plus RealAmp Kit.

The PCR-based test kit, which received Emergency Use Authorization from the US Food and Drug Administration about a year ago, is designed to detect SARS-CoV-2 nucleic acid in nasal swab specimens and other samples. Rehovat, Israel-based Todos said it will work with Osang to expand authorized use of the test to include saliva samples.

Todos said that the agreement with Osang allows it to sell, market, and distribute the test in the US. Financial and other terms of the deal were not disclosed.

"As a result of our newly established supply chain in the United States, we will be able to deliver GeneFinder Plus kits anywhere in the US within 48 [hours] of ordering," Osang Chairman and CEO Dong-Hyun Lee said in a statement.

SG Blocks, which designs and builds structures using maritime-grade shipping containers, also holds US distribution rights to the GeneFinder COVID-19 test under a May 2020 agreement. In December, South Korea-based Osang inked a manufacturing and supply deal for the test with Nexus Dx.



The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.